Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Clinical trial NCT06340711 · RECRUITING

Trial details

NCT number: NCT06340711
Sponsor: Weill Medical College of Cornell University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Start date: 2024-04-25
Primary completion: 2028-04-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.